Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.55 |
| ▸ | PGR | P06401 | 2/20 | 0.55 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | PTPRA | P18433 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.39 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8862654 | 0.81 | FDPS (0.47) | NR3C1PGRFDPSCYP1A2PTPRA | |
| SCHEMBL4133085 | 0.80 | CYP2C19 (0.47) | NR3C1PGRCYP1A2ALDH1A1TSHR | |
| SCHEMBL3657467 | 0.79 | PGR (0.50) | NR3C1PGRCYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL28444192 | 0.78 | FDPS (0.51) | FDPSCYP1A2PTPRASMN1; SMN2ALDH1A1 | |
| SCHEMBL17801002 | 0.78 | FDPS (0.51) | FDPSCYP1A2PTPRASMN1; SMN2ALDH1A1 | |
| SCHEMBL1634398 | 0.78 | NR3C1 (0.52) | NR3C1PGRFDPS | |
| SCHEMBL18773511 | 0.77 | RAB9A (0.46) | FDPSCYP1A2PTPRASMN1; SMN2ALDH1A1 | |
| SCHEMBL29694017 | 0.76 | CYP1A2 (0.53) | FDPSCYP1A2PTPRASMN1; SMN2ALDH1A1 | |
| SCHEMBL9092131 | 0.76 | CYP1A2 (0.53) | FDPSCYP1A2PTPRASMN1; SMN2ALDH1A1 | |
| SCHEMBL294785 | 0.76 | CYP1A2 (0.53) | FDPSCYP1A2PTPRASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1895999-A1 | USE OF NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | Schering Aktiengesellschaft (DE) | 2008-03-12 | — | — | EP | claimed |
| EP-1467982-B8 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA (US) | 2007-04-11 | — | — | EP | claimed |
| US-7189758-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | claimed |
| WO-2007022824-A1 | USE OF NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-01 | — | — | WO | claimed |
| US-20060293317-A1 | Use of non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | US | claimed |
| EP-1467982-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMA (US) | 2006-11-22 | — | — | EP | claimed |
| US-20060030561-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | US | claimed |
| EP-1467982-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-20 | — | — | EP | claimed |
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | claimed |
| WO-2003059899-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| CN-101878026-B | Pharmacological adjunctive therapy associated with glaucoma filtration surgery | BAUSCH & LOMB | 2013-11-20 | — | — | CN | disclosed |
| CN-101553214-B | Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy | BAUSCH & LOMB INCORPROATED | 2012-12-26 | — | — | CN | disclosed |
| CN-101484187-B | Composition comprising dissociated glucocorticoid receptor agonist and immunosuppressant for treating dry eye | BAUSCH & LOMB INCORPROATED | 2012-12-26 | — | — | CN | disclosed |
| CN-101969950-A | Compositions comprising a dissociated glucocorticoid receptor agonist for treating or controlling anterior-segment inflammation | BAUSCH & LOMB | 2011-02-09 | — | — | CN | disclosed |
| CN-101878026-A | Pharmacological adjunctive therapy associated with glaucoma filtration surgery | BAUSCH & LOMB | 2010-11-03 | — | — | CN | disclosed |
| US-20060030561-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| US-6960581-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1467982-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003059899-A1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL FORMULATIONS CONTAINING THEM AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 227/4885FDPS 3241/4885 |
| US-20060293317-A1 | Use of non-steroidal progesterone receptor modulators | SHBG, PGR, NR5A1 | NR3C1 32/4885PGR 2/4885FDPS 900/4885 |
| US-20060030561-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | NR3C1, MC2R, NR3C2 | NR3C1 1/4885PGR 80/4885FDPS 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.